INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.600
+0.070 (4.58%)
At close: Oct 29, 2026, 4:00 PM EDT
1.595
-0.005 (-0.31%)
Pre-market: Oct 30, 2026, 6:23 AM EDT
INmune Bio Employees
INmune Bio had 21 employees as of December 31, 2025. The number of employees decreased by 1 or 4.55% compared to the previous year. That makes INmune Bio the 38,220th largest employer in the world and 5,470th in the United States.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$876,952
Market Cap
49.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | 5 | 29.41% | 13 | 9 |
| Dec 31, 2023 | 17 | 7 | 70.00% | 11 | 6 |
| Dec 31, 2022 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2021 | 10 | 5 | 100.00% | 10 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Biomea Fusion | 37 |
| Actinium Pharmaceuticals | 27 |
| ImageneBio | 18 |
| Instil Bio | 17 |
| Serina Therapeutics | 16 |
| Apollomics | 14 |
| Alterity Therapeutics | 11 |
| Dogwood Therapeutics | 8 |
INMB News
- 22 hours ago - INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th - GlobeNewsWire
- 1 day ago - INmune Bio announces $4.5M registered direct offering - TheFly
- 2 days ago - INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 8 days ago - INmune Bio Enters Agreement to Distribute Its Ebstrocel Treatment - TipRanks
- 9 days ago - INmune Bio submits Ebstrocel pre-MAA package to MHRA - TheFly
- 9 days ago - INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 - GlobeNewsWire
- 9 days ago - INmune Bio enters Ebstrocel master services agreement with Uniphar Durbin - TheFly
- 9 days ago - INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar - GlobeNewsWire